Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy ...

PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six ...

Last November, Pyxis revealed it would continue to focus on PYX-201 as its lead asset, while pausing other early-stage ...

Pyxis Oncology (PYXS) announced preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple types of solid tumors. PYX-201, the company’s lead clinical drug ...

Researchers from Pyxis Oncology Inc. presented preclinical data for PYX-201, an antibody drug conjugate (ADC) that targets extra domain B of fibronectin (EDB+FN).

Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Sam Slutsky has given his Buy rating due to a combination of factors that highlight the potential of Pyxis ...

TUCSON, Ariz., Oct. 23, 2024 /PRNewswire/ -- Pyx Health, the leading social health platform addressing loneliness, today announced that Brett Ehrhardt has joined the company as Chief Financial ...

PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front ...